Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The investigators design a phase II clinical study to explore the efficacy and safety of
Transarterial Chemoembolization (TACE) + Lenvatinib + Icaritin soft capsules in patients with
Unresectable, non-metastatic hepatocellular carcinoma and to analyze potential biomarkers of
therapeutic response.